Atlas Trials

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial NCT02734771 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02734771
Sponsor
Patrick Reagan
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-Cell Lymphoma
Start date
2016-06-01
Primary completion
2025-12-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.